SCHEMBL4094983

SCHEMBL4094983

Cc1ccc(S(=O)(=O)Nc2cccc(C(=O)Nc3ccccc3C(=O)O)c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.66
KMT2A Q03164 11/20 0.66
PTGES O14684 1/20 0.63
ALOX5 P09917 1/20 0.63
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
HPGD P15428 1/20 0.60
TCF4 P15884 1/20 0.59
CTNNB1 P35222 1/20 0.59
PKM P14618 1/20 0.59
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
MAPT P10636 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
HTT P42858 1/20 0.58
RECQL P46063 1/20 0.58
EGFR P00533 1/20 0.57
FGFR1 P11362 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26808973 0.89 TCF4 (0.69) MEN1KMT2ALMNAHPGDTCF4
SCHEMBL14420811 0.89 KMT2A (0.64) MEN1KMT2APKMEGFRFGFR1
SCHEMBL4093101 0.89 KMT2A (0.65) MEN1KMT2APKMMAPT
SCHEMBL13870858 0.89 MEN1 (0.82) MEN1KMT2APTGESALOX5ALDH1A1
SCHEMBL26808980 0.89 KMT2A (0.80) MEN1KMT2APTGESALOX5PKM
SCHEMBL6352083 0.87 METAP2 (0.67) MEN1KMT2APTGESALOX5TCF4
SCHEMBL6720181 0.85 MEN1 (0.85) MEN1KMT2APKMMAPTCASP3
SCHEMBL26808968 0.83 KMT2A (0.68) MEN1KMT2APTGESALOX5ALDH1A1
SCHEMBL23200311 0.82 MEN1 (0.66) MEN1KMT2AALDH1A1LMNAHPGD
SCHEMBL14855770 0.82 KCNA5 (0.65) MEN1KMT2AALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
EP-1758571-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM Pharma A/S (DK) 2007-03-07 EP disclosed
WO-2005115374-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM PHARMA A/S (DK) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use NR1H2, NR1H3, HRH2 MEN1 2859/4885KMT2A 2570/4885PTGES 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.